Melanoma: cutaneous events predict better response to immunotherapy

  • Chan L & al.
  • J Am Acad Dermatol
  • 21 Jun 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Cutaneous adverse events (AEs) are associated with improved PFS in patients with stage IIIC/IV melanoma treated with PD-1 inhibitor (pembrolizumab or nivolumab).

Why this matters

  • This study adds evidence to the model that development of immune-mediated AEs correlates with treatment response to immunotherapy.

Key results

  • 40.2% of patients experienced ≥1 cutaneous AE (eczema, lichenoid reaction, or vitiligo-like depigmentation).
  • Patients who developed ≥1 cutaneous AE had lower risk for disease progression/mortality (HR, 0.460; P=.025) compared with patients who did not.
    • This result was also significant in landmark analysis at 6 (HR, 0.45; P=.045) and 12 (HR, 0.35; P=.020) months.

Study design

  • 82 patients with stage IIIC/IV melanoma treated with pembrolizumab or nivolumab were analyzed for cutaneous AEs and PFS.
  • Funding: None.

Limitations

  • Small patient sample size.
  • No multivariate analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit